Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on EIGR’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Eiger BioPharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for EIGR
In the past 30 days, one estimate have gone higher for Eiger BioPharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of $1.32 a share 30 days ago, to a loss of 1 cent today, a move of 24.2%.
Current Year Estimates for EIGR
Meanwhile, Eiger BioPharmaceuticals’ current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $4.96 per share 30 days ago to a loss of $4.50 per share today, a move of 9.3%.
Eiger BioPharmaceuticals, Inc. Price and Consensus
Bottom Line
The stock has also started to move higher lately, adding 15.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Image: Bigstock
Why Eiger BioPharmaceuticals (EIGR) Could Be Positioned for a Surge
Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on EIGR’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Eiger BioPharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for EIGR
In the past 30 days, one estimate have gone higher for Eiger BioPharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of $1.32 a share 30 days ago, to a loss of 1 cent today, a move of 24.2%.
Current Year Estimates for EIGR
Meanwhile, Eiger BioPharmaceuticals’ current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $4.96 per share 30 days ago to a loss of $4.50 per share today, a move of 9.3%.
Eiger BioPharmaceuticals, Inc. Price and Consensus
Eiger BioPharmaceuticals, Inc. Price and Consensus | Eiger BioPharmaceuticals, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 15.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>